DeuteRx Obtains $2,800,000 Seed Funding Round

  • Feed Type
  • Date
    10/1/2015
  • Company Name
    DeuteRx
  • Mailing Address
    300 Brickstone Square Andover, MA 01810 USA
  • Company Description
    DeuteRx is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications.
  • Website
    http://www.deuterx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $2,800,000
  • Transaction Round
    Seed
  • Proceeds Purposes
    The company intends to use the funds for the advancement of its lead program, DRX-065, into human clinical trials for the treatment of adrenoleukodystrophy (ALD).
  • M&A Terms
  • Venture Investor
    Undisclosed